CV Sciences, Inc. reported revenue of $3.6 million for the first quarter of 2025, compared to $4.0 million for the first quarter of 2024. The company recognized a gross margin of 46.0% for the quarter, compared to 46.3% in the prior year period.
The company achieved an improved adjusted EBITDA loss of $0.3 million for the first quarter of 2025, compared to an adjusted EBITDA loss of $0.5 million for the first quarter of 2024. This indicates continued progress in reducing operational losses.
CV Sciences also entered into a financing agreement with an institutional investor, securing net proceeds of $1.2 million. This financing event increased the cash balance to $0.8 million at quarter-end, up from $0.5 million at the end of 2024, addressing immediate liquidity needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.